Skip to main content

IQVIA

AI Clinical Trials Market to Hit $7.32B by 2034, 15.5% CAGR

AI Clinical Trials Market to Hit $7.32B by 2034, 15.5% CAGR

Pune, India – September 25, 2026 -- The global AI in Clinical Trials Market is set to more than triple from USD 2 billion in 2025 to USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate, according to Maximize Market Research.

Pharmaceutical firms accelerate AI adoption to cut trial delays

Pharmaceutical and biotechnology companies, along with contract research organizations, hospitals and research institutes, are deploying machine learning, natural language processing and deep learning to speed patient screening, cohort selection, trial design and large-scale data analysis. These tools are applied across Phase I, Phase II and Phase III trials for patient recruitment, safety monitoring, drug discovery and personalized medicine.

ProBio, Kun Tuo Partner to Fast-Track Cell and Gene Therapy Trials in China

ProBio, Kun Tuo Partner to Fast-Track Cell and Gene Therapy Trials in China

Hopewell, N.J. – September 18, 2026 -- ProBio, a global contract development and manufacturing organization (CDMO), has struck a strategic collaboration with Kun Tuo, an IQVIA-owned clinical research organization (CRO) in China, to integrate manufacturing and clinical trial execution for advanced therapies.

Partnership links CDMO manufacturing with CRO trial operations in China

The alliance combines ProBio's biologics and cell and gene therapy (CGT) development and manufacturing platform with Kun Tuo's clinical trial management network, targeting faster Investigator-Initiated Trials (IITs) for global biopharma sponsors entering the Chinese market. The integrated offering spans Chemistry, Manufacturing and Controls (CMC), non-clinical studies, and clinical operations under a single coordinated pathway.